Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-Tau antibody - Denali Therapeutics/Takeda

Next Previous
X
Search
Drug Profile

Anti-Tau antibody - Denali Therapeutics/Takeda

Alternative Names: ATV:BACE1/Tau; ATV:Tau; ATV:Tau programme

Latest Information Update: 28 Dec 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Denali Therapeutics Inc; Takeda
  • Developer Denali Therapeutics Inc
  • Class Antibodies; Antidementias; Neuroprotectants
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 28 Dec 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral)
  • 28 Feb 2019 Denali Therapeutics amends the agreement with Takeda to to replace the bispecific ATV:BACE1/Tau programme with the ATV:Tau programme
  • 23 Mar 2018 Denali Therapeutics intends to file an IND or CTA application in 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top